- NTPC's non-core plans flounder
- JSW Steel: Better placed than peers
- Valuations, drug pricing policy limit upsides for Apollo Hospitals
- BHEL: Results in line, but outlook remains bleak
- The bluff must be called
- Ranbaxy's dark chapter
- CARE's global JV to be christened ARC Ratings
- SBI's asset quality hasn't hit a bottom
- Tata Steel: loss doesn't bite as much as numbers suggest
- Daiichi set to raise Japanese strength in Ranbaxy for image lift
- A gallery of disruptive technologies
- The $33-trn tech payoff
- Samsung's Galaxy S4 hits 10-mn mark
- Subbarao agreed with minority of advisors, show minutes
- NTPC's non-core plans flounder
- US Fed can terminate quantitative easing in 2014: Jan Lambregts
- JSW Steel: Better placed than peers
- Valuations, drug pricing policy limit upsides for Apollo Hospitals
- BHEL: Results in line, but outlook remains bleak
- Running winners, cutting losers


